查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024186

液態生物檢體市場：按癌症類型、應用、生物標記、地點和產品分類的價格和銷售預測 - 高階主管指南、顧問指南及人工智慧的影響（2026-2030 年） - 第 9 版

Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Impact of Artificial Intelligence 2026-2030 (9th Edition)
出版日期: | 出版商: Howe Sound Research | 英文 602 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

市場概況：

液態生物檢體是指一系列診斷技術，它檢測血液和其他體液中存在的癌症相關生物標記物，而非傳統的組織樣本。這些檢測分析循環腫瘤DNA (ctDNA)、循環性腫瘤細胞(CTC)、遊離DNA (cfDNA)、外泌體、RNA片段以及其他由腫瘤釋放到血液中的分子訊號。液態生物檢體作為一種微創的替代手術切片檢查的方法，正受到越來越多的關注，因為它能夠實現更頻繁的檢測並更好地監測疾病進展。

2025年市場規模：81.4億美元；2030年市場規模：151億美元；複合年成長率：13.2%

液態生物檢體市場的成長與精準醫療和標靶癌症療法的推廣密切相關。腫瘤學領域的應用佔了該市場最大的佔有率，因為分子譜分析在指導接受標靶治療和免疫療法的患者的治療選擇方面發揮著越來越重要的作用。液態生物檢體技術能夠識別指南治療選擇的基因組突變、檢測新的抗藥性突變以及監測治療反應的長期變化。

與組織切片檢查相比的優勢

傳統的組織切片檢查是一種侵入性操作，會給患者帶來不適和相關風險，而且在檢測腫瘤異質性方面也存在局限性。由於腫瘤會隨時間推移而變化，並且會因轉移部位的不同而有所差異，因此從單一部位獲取組織樣本極具挑戰性。

液態生物檢體具有以下幾個重要優勢：

  • 透過血液採樣進行微創檢體採集
  • 治療期間可以進行多次檢查。
  • 檢測多個腫瘤部位的腫瘤異質性
  • 與切片檢查相比，快速結果報告
  • 提高患者依從性

這些特性使得可以對疾病進展和治療反應進行時間序列監測，使液態生物檢體在腫瘤學的臨床過程中特別有用。

生物標記的類型

液態生物檢體切片檢查可偵測體液中循環的多種腫瘤來源生物標記。應用最廣泛的生物標記是循環腫瘤DNA（ctDNA），它是由癌細胞釋放到血液中的DNA片段組成。 ctDNA分析可以識別癌症相關的基因突變、拷貝數變異和表觀遺傳改變。

循環性腫瘤細胞（CTC）是指從原發性或轉移性腫瘤釋放到血液中的完整癌細胞。這些細胞能夠提供有關腫瘤生物學特徵和轉移潛能的資訊。

無細胞DNA包含腫瘤來源和非腫瘤來源的DNA片段。先進的定序技術可以區分正常DNA和腫瘤DNA。

外泌體和細胞外囊泡不僅含有蛋白質，還含有 RNA 和 DNA 片段，這可能有助於深入了解腫瘤的生物學特徵。

表觀遺傳標記，如 DNA 甲基化模式，作為腫瘤存在和原發組織的重要指標，正引起人們的注意。

液態生物檢體中使用的技術

多種分子技術可用於檢測液態生物檢體中的生物標記。次世代定序（NGS）因其能夠同時分析多個基因和基因組區域而被廣泛應用。 NGS能夠進行全面的腫瘤譜分析並檢測多種突變類型。

聚合酵素鏈鎖反應(PCR) 和數位 PCR 方法可以高靈敏度地檢測已知突變，常用於標靶檢測。

微陣列技術和基於質譜的方法有時也會應用於特定領域。

生物資訊工具在解釋定序資料和區分真正的腫瘤訊號與背景雜訊方面發揮著至關重要的作用。

技術進步顯著提高了靈敏度，使得檢測即使是微量的循環腫瘤DNA都成為可能。

臨床應用

液態生物檢體技術已應用於多種臨床領域。

透過 ctDNA 分析識別出的基因組突變可以指示標靶治療或免疫療法是否合適，使治療方法選擇成為一個重要的應用案例。

治療監測是另一個重要的應用。 ctDNA水平隨時間的變化可以指示治療反應或疾病進展。

微量殘存疾病（MRD）檢測是一個新的應用領域，它利用液態生物檢體來識別治療後殘留的少量癌細胞。

癌症早期檢測是液態生物檢體技術最具長期應用前景的領域之一。多癌種早期檢測旨在症狀出現前識別癌症，從而提高存活率。

此外，液態生物檢體也用於臨床研究和開發，支持臨床試驗中生物標記的發現和患者分層。

市場促進因素

多種因素正在推動液態生物檢體市場的擴張。

精準醫療方法的日益普及，催生了對能夠指導治療決策的分子檢測的需求。

隨著標靶治療和免疫療法的進步，對基因組分析工具的需求日益成長。

定序技術的進步提高了分析靈敏度並降低了成本，這推動了其在臨床環境中的更廣泛應用。

隨著人們對癌症早期檢測技術的興趣日益濃厚，醫療保健機構和製藥公司紛紛增加了投資。

患者對微創診斷方法的接受度提高也促進了市場成長。

市場區隔

液態生物檢體市場可按生物標記類型、技術平台、臨床應用、最終用戶和地區進行細分。

就生物標記類型而言，循環腫瘤 DNA 佔比最大，其次是循環性腫瘤細胞和基於外泌體的檢測。

從技術角度來看，由於次世代定序能夠進行多基因分析，因此它是一個快速成長的領域。

臨床應用包括治療方法選擇、治療監測、復發檢測和早期癌症篩檢。

最終用戶包括醫院檢查室、參考實驗室、學術研究機構和進行臨床試驗的製藥公司。

北美是最大的區域市場，這得益於其強大的研究基礎設施和基因組檢測的高普及率。此外，隨著精準醫療計畫的擴展，歐洲和亞太地區的市場也在成長。

競爭格局

液態生物檢體市場包括領先的分子診斷公司、專業的生物技術公司以及專注於生物標記發現的新興企業。

競爭對手越來越注重開發能夠滿足多種臨床應用需求的綜合測試平台。

鑑於生物標記檢測在藥物研發中的重要性日益增加，診斷公司與製藥公司之間的策略合作已變得司空見慣。

生物資訊能力和基因組資料庫的存取權正成為重要的競爭優勢。

未來展望

隨著技術進步和臨床應用的不斷拓展，液態生物檢體市場預計將持續成長。尤其值得一提的是，從長遠來看，多種癌症的早期檢測蘊藏著巨大的商機。

定序技術、生物資訊學和生物標記發現的進步有望提高診斷能力並擴大臨床效用。

液態生物檢體技術有可能成為癌症篩檢、治療方法選擇和疾病監測的標準工具。

總體而言，液態生物檢體是分子診斷市場中一個快速發展的領域，預計將在未來的精準腫瘤學和個人化醫療中發揮核心作用。

目錄

第1章 市集指南

第2章：引言與市場定義

  • 什麼是液態生物檢體？
  • 序列革命
  • 市場定義
  • 調查方法
  • 展望：醫療保健和體外診斷行業

第3章 市場概覽

  • 參與企業充滿活力的市場
    • 學術研究辦公室
    • 診斷測試開發人員
    • 測量儀器供應商
    • 化學品/試劑供應商
    • 病理檢測用品供應商
    • 獨立臨床實驗室
    • 國家/地區公共研究機構
    • 醫院檢查室
    • 醫師診所檢查室(POLS)
    • 審計機構
    • 認證機構
  • 切片檢查的應用
  • 切片檢查部位
  • 現況分析—切片檢查分析
  • 癌症證據—液態生物檢體技術
  • 癌症治療方案危機
  • 產業結構的影響

第4章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 測量與自動化
  • 診斷技術發展

第5章：液態生物檢體的最新趨勢

第6章：主要企業概況

  • Admera Health, LLC
  • Abbott Laboratories
  • AccuraGen Inc.
  • Acuamark Diagnostics
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • Applied DNA Sciences
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • Berkley Lights
  • BGI Genomics Co. Ltd
  • BillionToOne
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Burning Rock
  • Cardiff Oncology
  • CareDx
  • Caris Molecular Diagnostics
  • CellCarta
  • CellMax Life
  • Cepheid（Danaher）
  • Circulogene
  • Cizzle Biotech
  • Clearbridge Biomedics
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Dxcover
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exact Sciences
  • Fluxion Biosciences（Cell Microsystems）
  • Freenome
  • Fyr Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • Haystack Oncology（Quest Dx）
  • iCellate
  • ICON PLC
  • Illumina
  • Incell Dx
  • Inivata
  • INOVIQ
  • Invitae Corporation
  • J&J Innovative Medicine
  • Lucence Health
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics
  • Nanostring
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • Novogene
  • On-Chip Biotechnologies
  • Oncocyte
  • OncoDNA
  • Oncimmune
  • Oxford Nanopore Technologies
  • PamGene
  • Panagene
  • Personalis
  • PGDx（Labcorp）
  • PrecisionMed
  • Predicine
  • Predictive Oncology
  • Prenetics
  • Promega
  • Qiagen
  • Rarecells SAS
  • RareCyte
  • Revvity
  • Roche Diagnostics
  • Saga Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Standard BioTools
  • Stilla Technologies
  • Superfluid Dx
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific
  • Todos Medical
  • Ultima Genomics
  • Veracyte
  • VolitionRX
  • Vortex Biosciences

第7章：全球液態生物檢體診斷市場

  • 全球市場各國概覽
  • 癌症相關市場概覽
  • 全球市場概覽（按應用領域分類）
  • 區域全球市場概覽
  • 全球市場概覽（按市場類別分類）
  • 全球市場概覽（按產品類別分類）

第8章 全球液態生物檢體診斷市場－以癌症類型分類

  • 乳癌
  • 結腸癌
  • 子宮頸癌
  • 肺癌
  • 攝護腺癌
  • 其他

第9章 全球液態生物檢體診斷市場－按應用領域分類

  • 篩檢
  • 診斷
  • 治療
  • 監測

第10章：全球液態生物檢體診斷市場－按地區分類

  • 醫院檢查室
  • 檢查服務
  • 門診檢查室
  • 其他

第11章 全球液態生物檢體診斷市場－按標記物分類

  • 循環性腫瘤細胞
  • 無細胞DNA
  • 小囊泡
  • 其他

第12章 全球液態生物檢體診斷市場－依產品分類

  • 成套工具
  • 裝置
  • 服務

第13章附錄

表格一覽

圖表清單

簡介目錄
Product Code: CANLB 426

Market Overview:

Liquid biopsy refers to a group of diagnostic technologies that detect cancer-related biomarkers in blood or other body fluids rather than traditional tissue samples. These tests analyze circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, RNA fragments, and other molecular signals released by tumors into the bloodstream. Liquid biopsy has attracted significant attention because it offers a minimally invasive alternative to surgical biopsy procedures, enabling more frequent testing and improved monitoring of disease progression.

Market Size 2025: USD $8.14B Market Size 2030: USD $15.1B CAGR: 13.2%

Growth in the liquid biopsy market is closely linked to the expansion of precision medicine and targeted cancer therapies. Oncology applications represent the largest segment of the market, as molecular profiling increasingly guides treatment selection for patients receiving targeted therapies or immunotherapies. Liquid biopsy technologies enable identification of genomic alterations that can inform therapy selection, detect emerging drug resistance mutations, and monitor treatment response over time.

Advantages Compared with Tissue Biopsy

Traditional tissue biopsies involve invasive procedures that may be associated with patient discomfort, procedural risk, and limited ability to capture tumor heterogeneity. Tumors may evolve over time or vary across metastatic sites, creating challenges for single-site tissue sampling.

Liquid biopsy offers several important advantages:

  • minimally invasive sampling through blood draw
  • ability to perform repeated testing during treatment
  • detection of tumor heterogeneity across multiple tumor sites
  • faster turnaround time compared with surgical biopsy
  • improved patient compliance

These characteristics support longitudinal monitoring of disease progression and treatment response, making liquid biopsy particularly valuable in oncology care pathways.

Biomarker Types

Liquid biopsy tests detect multiple types of tumor-derived biomarkers circulating in body fluids. The most widely used biomarker is circulating tumor DNA, which consists of fragmented DNA released into the bloodstream by tumor cells. Analysis of ctDNA can identify genetic mutations, copy number variations, and epigenetic alterations associated with cancer.

Circulating tumor cells represent intact cancer cells shed into the bloodstream from primary or metastatic tumors. These cells can provide information about tumor biology and metastatic potential.

Cell-free DNA includes both tumor-derived and non-tumor-derived DNA fragments. Advanced sequencing methods allow differentiation between normal and tumor DNA.

Exosomes and extracellular vesicles contain proteins, RNA, and DNA fragments that may provide additional insights into tumor biology.

Epigenetic markers such as DNA methylation patterns are emerging as important indicators of tumor presence and tissue of origin.

Technologies Used in Liquid Biopsy

Several molecular technologies are used to detect liquid biopsy biomarkers. Next-generation sequencing (NGS) is widely used because it allows simultaneous analysis of multiple genes and genomic regions. NGS supports comprehensive tumor profiling and detection of multiple mutation types.

Polymerase chain reaction (PCR) and digital PCR methods provide highly sensitive detection of known mutations and are commonly used in targeted assays.

Microarray technologies and mass spectrometry-based approaches may also be used in certain applications.

Bioinformatics tools play an essential role in interpreting sequencing data and distinguishing true tumor signals from background noise.

Technological improvements have significantly increased sensitivity, allowing detection of very low levels of circulating tumor DNA.

Clinical Applications

Liquid biopsy technologies are used across several clinical applications.

Therapy selection represents an important use case, as genomic alterations identified through ctDNA analysis may indicate eligibility for targeted therapies or immunotherapies.

Treatment monitoring is another key application. Changes in ctDNA levels over time may indicate treatment response or disease progression.

Minimal residual disease (MRD) detection is an emerging application in which liquid biopsy tests identify small amounts of cancer remaining after treatment.

Early cancer detection represents one of the largest long-term opportunities for liquid biopsy technologies. Multi-cancer early detection tests aim to identify cancer before symptoms develop, potentially improving survival outcomes.

Liquid biopsy is also used in clinical research and drug development to support biomarker discovery and patient stratification in clinical trials.

Market Drivers

Several factors are driving expansion of the liquid biopsy market.

The increasing adoption of precision medicine approaches is creating demand for molecular testing capable of guiding therapy decisions.

Growth in targeted therapies and immunotherapies is increasing the need for genomic profiling tools.

Advances in sequencing technologies have improved analytical sensitivity and reduced costs, supporting broader clinical adoption.

Interest in early cancer detection technologies is attracting investment from healthcare providers and pharmaceutical companies.

Improved patient acceptance of minimally invasive testing methods is also supporting market growth.

Market Segmentation

The liquid biopsy market can be segmented by biomarker type, technology platform, clinical application, end user, and geographic region.

By biomarker type, circulating tumor DNA represents the largest segment, followed by circulating tumor cells and exosome-based assays.

By technology, next-generation sequencing represents a rapidly growing segment due to its ability to support multi-gene analysis.

Clinical applications include therapy selection, treatment monitoring, recurrence detection, and early cancer screening.

End users include hospital laboratories, reference laboratories, academic research institutions, and pharmaceutical companies conducting clinical trials.

North America represents the largest geographic market due to strong research infrastructure and high adoption of genomic testing. Europe and Asia-Pacific markets are also expanding as precision medicine initiatives increase.

Competitive Landscape

The liquid biopsy market includes large molecular diagnostics companies, specialized biotechnology firms, and emerging companies focused on biomarker discovery.

Competition is increasingly focused on development of comprehensive testing platforms capable of supporting multiple clinical applications.

Strategic partnerships between diagnostic companies and pharmaceutical companies are common due to the importance of biomarker testing in drug development.

Bioinformatics capabilities and access to genomic databases are becoming important competitive differentiators.

Future Outlook

The liquid biopsy market is expected to continue expanding as technologies improve and clinical applications broaden. Multi-cancer early detection testing represents a particularly significant long-term opportunity.

Advances in sequencing technologies, bioinformatics, and biomarker discovery are expected to improve diagnostic performance and expand clinical utility.

Liquid biopsy technologies may become standard tools for cancer screening, therapy selection, and disease monitoring.

Overall, liquid biopsy represents a rapidly evolving segment of the molecular diagnostics market that is expected to play a central role in the future of precision oncology and personalized medicine.

Table of Contents

1 Market Guides

  • 1.1 Liquid Biopsy Market - Strategic Situation Analysis
    • 1.1.1 Strategic Role in Precision Medicine
    • 1.1.2 Scientific and Clinical Validation Challenges
    • 1.1.3 Regulatory Complexity and Evidence Requirements
    • 1.1.4 Reimbursement and Health Economic Value
    • 1.1.5 Technology Evolution and Competitive Dynamics
    • 1.1.6 Expansion of Multi-Cancer Early Detection Testing
    • 1.1.7 Dependence on Oncology Drug Development
    • 1.1.8 Geographic Market Dynamics
    • 1.1.9 Outlook and Strategic Implications
  • 1.2 Guide for Executives, Marketing, Sales, and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors
  • 1.4 Impact of Artificial Intelligence on Liquid Biopsy Market

2 Introduction and Market Definition

  • 2.1 What is Liquid Biopsy?
  • 2.2 The Sequencing Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Methodology
    • 2.4.1 Methodology
    • 2.4.2 Sources
    • 2.4.3 Authors
  • 2.5 Perspective: Healthcare and the IVD Industry
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Instrumentation Supplier
    • 3.1.4 Chemical/Reagent Supplier
    • 3.1.5 Pathology Supplier
    • 3.1.6 Independent Clinical Laboratory
    • 3.1.7 Public National/regional Laboratory
    • 3.1.8 Hospital Laboratory
    • 3.1.9 Physicians Office Lab (POLS)
    • 3.1.10 Audit Body
    • 3.1.11 Certification Body
  • 3.2 Using Biopsies
    • 3.2.1 Cancer
    • 3.2.2 Precancerous conditions
    • 3.2.3 Inflammatory conditions
  • 3.3 Biopsy Sites
  • 3.4 The Situation Today - Biopsy Analysis
  • 3.5 Evidence of Cancer - Liquid Biopsy Technology
    • 3.5.1 The Big Picture on Liquid Biopsy Technology
    • 3.5.2 The Role of CTCs
    • 3.5.3 Application of CTCs
    • 3.5.4 CellSearch Detection- Ultimate Sensitivity
    • 3.5.5 Epic Sciences Detection- Imaging Takes the Lead
    • 3.5.6 Maintrac Detection - The Microscope
    • 3.5.7 Other Methods
    • 3.5.8 ctDNA Role
    • 3.5.9 ctDNA Applications
    • 3.5.10 Exosomes and Micro Vesicles - New Kid on the Block
    • 3.5.11 The Multiple Play
  • 3.6 Cancer Treatment Protocol Under Siege
    • 3.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
    • 3.6.2 The Cancer Screening Market Opportunity
      • 3.6.2.1 GRAIL - What Is It?
    • 3.6.3 Cancer Management vs. Diagnosis
      • 3.6.3.1 The Role of Risk Assessment
      • 3.6.3.2 Managing Therapy
      • 3.6.3.3 Monitoring Disease - What Is It?
    • 3.6.4 Phases of Adoption - Looking into The Future
    • 3.6.5 The Promise of Liquid Biopsy
  • 3.7 Structure of Industry Plays a Part
    • 3.7.1 Hospital Testing Share
    • 3.7.2 Economies of Scale
      • 3.7.2.1 Hospital vs. Central Lab
    • 3.7.3 Physician Office Lab's
    • 3.7.4 Physician's and POCT

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Non-Invasive Game Changer
    • 4.1.2 Lower Cost
    • 4.1.3 Greater Accuracy
    • 4.1.4 Wide Range of Potential Uses
    • 4.1.5 Aging Population
  • 4.2 Factors Limiting Growth
    • 4.2.1 Lower prices
    • 4.2.2 Lack of Standards
    • 4.2.3 Protocol Resistance
    • 4.2.4 Initial Adoption Cost
    • 4.2.5 Conclusion
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 Bioinformatics Plays a Role
  • 4.4 Diagnostic Technology Development
    • 4.4.1 Next Generation Sequencing Fuels a Revolution
    • 4.4.2 Impact of NGS on pricing
    • 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4 CGES Testing, A Brave New World
    • 4.4.5 Biochips/Giant magneto resistance based assay

5 Liquid Biopsy Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 Liquid Biopsy Firm QCDx Closes Financing
  • 5.3 LabCorp Launches Liquid Biopsy
  • 5.4 OncoHelix, AstraZeneca to Provide Prostate Cancer Liquid Biopsy Testing
  • 5.5 Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M
  • 5.6 GeneCentric Therapeutics Launches ExpressCT Liquid Biopsy Platform
  • 5.7 Syantra Closes Financing
  • 5.8 Concerns Over Grail Test Effectiveness
  • 5.9 Guardant Health Sues Tempus for Patent Infringement
  • 5.10 Delfi Dx Liquid Biopsy Technology Shows Promise
  • 5.11 Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx
  • 5.12 Grail Details TBE Method for Cancer Monitoring
  • 5.13 Naveris HPV Liquid Biopsy Test Gets Medicare Coverage
  • 5.14 Personalis NeXT Personal Dx Early-Access Program
  • 5.15 Liquid Biopsy Shortens Time to Treatment
  • 5.16 Guardant Health MRD Test Garners Coverage
  • 5.17 IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership
  • 5.18 FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic
  • 5.19 Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test
  • 5.20 GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test
  • 5.21 Sophia Genetics to Commercialize Liquid Biopsy Test
  • 5.22 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx
  • 5.23 Liquid Biopsy Startup Haystack Oncology Raises $56M
  • 5.24 Hedera Dx to Launch Liquid Biopsy Streamlined Platform
  • 5.25 PamGene Expanding Liquid Biopsy Assays
  • 5.26 Liquid Biopsy Firm Hedera Dx Raises Euro 14M
  • 5.27 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx
  • 5.28 Precision Oncology Dx Access Varies Widely in Europe
  • 5.29 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic
  • 5.30 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
  • 5.31 BillionToOne Launches First Liquid Biopsy Products
  • 5.32 Dxcover Advances Multicancer Detection Platform
  • 5.33 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test
  • 5.34 Illumina Sues Guardant Health Over Patents
  • 5.35 Invitae to Expand Cancer Testing Portfolio
  • 5.36 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
  • 5.37 IVBH Bio Takes Aim at With Liquid Biopsy Incubator
  • 5.38 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
  • 5.39 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
  • 5.40 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
  • 5.41 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
  • 5.42 Liquid Biopsy Startup BioCaptiva Raises Pound 1M in Seed Funding
  • 5.43 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
  • 5.44 Bio-Techne to Acquire Asuragen for up to $320M
  • 5.45 Personalis Broadens Liquid Biopsy Offering
  • 5.46 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
  • 5.47 Delfi Diagnostics Plans Multi-Cancer Screening Test
  • 5.48 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment
  • Response
  • 5.49 Liquid Biopsy NGS Panels - Diverse Test Claims
  • 5.50 CMS Colon Cancer Screening Memo Bodes Well for Assays
  • 5.51 Natera Liquid Biopsy Test Coverage to Expand
  • 5.52 Freenome Closes Financing to Support Early Cancer Detection Trial
  • 5.53 C$2.6M Liquid Biopsy Initiative
  • 5.54 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
  • 5.55 Liquid Biopsy Shows Promise as Screen for Cancers
  • 5.56 Inivata launches RaDaR-TM for the detection of residual disease and recurrence
  • 5.57 Liquid Biopsy Assay Detects 50+ Types of Cancer
  • 5.58 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

6 Profiles of Key Players

  • 6.1 Admera Health, LLC
  • 6.2 Abbott Laboratories
  • 6.3 AccuraGen Inc.
  • 6.4 Acuamark Diagnostics
  • 6.5 Agilent
  • 6.6 Amoy Diagnostics Co., Ltd.
  • 6.7 Anchor Dx
  • 6.8 ANGLE plc
  • 6.9 Applied DNA Sciences
  • 6.10 ARUP Laboratories
  • 6.11 AVIVA Systems Biology
  • 6.12 Baylor Miraca Genetics Laboratories
  • 6.13 Beckman Coulter Diagnostics (Danaher)
  • 6.14 Becton, Dickinson and Company
  • 6.15 Berkley Lights
  • 6.16 BGI Genomics Co. Ltd
  • 6.17 BillionToOne
  • 6.18 Bioarray Genetics
  • 6.19 Biocartis
  • 6.20 Biocept, Inc.
  • 6.21 Biodesix Inc.
  • 6.22 BioFluidica
  • 6.23 Biolidics Ltd
  • 6.24 bioMerieux Diagnostics
  • 6.25 Bioneer Corporation
  • 6.26 Bio-Rad Laboratories, Inc
  • 6.27 Bio-Techne
  • 6.28 Bioview
  • 6.29 Burning Rock
  • 6.30 Cardiff Oncology
  • 6.31 CareDx
  • 6.32 Caris Molecular Diagnostics
  • 6.33 CellCarta
  • 6.34 CellMax Life
  • 6.35 Cepheid (Danaher)
  • 6.36 Circulogene
  • 6.37 Cizzle Biotech
  • 6.38 Clearbridge Biomedics
  • 6.39 Clinical Genomics
  • 6.40 Cytolumina Technologies Corp.
  • 6.41 Datar Cancer Genetics Limited
  • 6.42 Diagnologix LLC
  • 6.43 Dxcover
  • 6.44 Element Biosciences
  • 6.45 Enzo Biochem
  • 6.46 Epic Sciences
  • 6.47 Epigenomics AG
  • 6.48 Eurofins Scientific
  • 6.49 Exact Sciences
  • 6.50 Fluxion Biosciences (Cell Microsystems)
  • 6.51 Freenome
  • 6.52 Fyr Diagnostics
  • 6.53 GeneFirst Ltd.
  • 6.54 Genetron Holdings
  • 6.55 GILUPI Nanomedizin
  • 6.56 Guardant Health
  • 6.57 HansaBiomed
  • 6.58 Haystack Oncology (Quest Dx)
  • 6.59 iCellate
  • 6.60 ICON PLC
  • 6.61 Illumina
  • 6.62 Incell Dx
  • 6.63 Inivata
  • 6.64 INOVIQ
  • 6.65 Invitae Corporation
  • 6.66 J&J Innovative Medicine
  • 6.67 Lucence Health
  • 6.68 Lunglife AI Inc
  • 6.69 MDNA Life SCIENCES, Inc.
  • 6.70 MDx Health
  • 6.71 Menarini Silicon Biosystems
  • 6.72 Mesa Laboratories, Inc.
  • 6.73 Millipore Sigma
  • 6.74 Miltenyi Biotec
  • 6.75 miR Scientific
  • 6.76 Myriad Genetics
  • 6.77 Nanostring
  • 6.78 NantHealth, Inc.
  • 6.79 Natera
  • 6.80 NeoGenomics
  • 6.81 Novogene
  • 6.82 On-Chip Biotechnologies
  • 6.83 Oncocyte
  • 6.84 OncoDNA
  • 6.85 Oncimmune
  • 6.86 Oxford Nanopore Technologies
  • 6.87 PamGene
  • 6.88 Panagene
  • 6.89 Personalis
  • 6.90 PGDx (Labcorp)
  • 6.91 PrecisionMed
  • 6.92 Predicine
  • 6.93 Predictive Oncology
  • 6.94 Prenetics
  • 6.95 Promega
  • 6.96 Qiagen
  • 6.97 Rarecells SAS
  • 6.98 RareCyte
  • 6.99 Revvity
  • 6.100 Roche Diagnostics
  • 6.101 Saga Diagnostics
  • 6.102 Screencell
  • 6.103 Siemens Healthineers
  • 6.104 simfo GmbH
  • 6.105 Singlera Genomics Inc.
  • 6.106 Singular Genomics
  • 6.107 Standard BioTools
  • 6.108 Stilla Technologies
  • 6.109 Superfluid Dx
  • 6.110 Sysmex Inostics
  • 6.111 Tempus Labs, Inc.
  • 6.112 Thermo Fisher Scientific
  • 6.113 Todos Medical
  • 6.114 Ultima Genomics
  • 6.115 Veracyte
  • 6.116 VolitionRX
  • 6.117 Vortex Biosciences

7 The Global Market for Liquid Biopsy Diagnostics

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Cancer - Overview
    • 7.2.1 Table - Global Market by Cancer
    • 7.2.2 Chart - Global Market by Cancer - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Cancer - Base Year
    • 7.2.4 Chart - Global Market by Cancer - End Year
    • 7.2.5 Chart - Global Market by Cancer - Share by Year
    • 7.2.6 Chart - Global Market by Cancer - Segments Growth
  • 7.3 Global Market by Usage - Overview
    • 7.3.1 Table - Global Market by Usage
    • 7.3.2 Chart - Global Market by Usage - Base/Final Year Comparison
    • 7.3.3 Chart - Global Market by Usage - Base Year
    • 7.3.4 Chart - Global Market by Usage - End Year
    • 7.3.5 Chart - Global Market by Usage - Share by Year
    • 7.3.6 Chart - Global Market by Usage - Segments Growth
  • 7.4 Global Market by Place - Overview
    • 7.4.1 Table - Global Market by Place
    • 7.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 7.4.3 Chart - Global Market by Place - Base Year
    • 7.4.4 Chart - Global Market by Place - End Year
    • 7.4.5 Chart - Global Market by Place - Share by Year
    • 7.4.6 Chart - Global Market by Place - Segments Growth
  • 7.5 Global Market by Marker - Overview
    • 7.5.1 Table - Global Market by Marker
    • 7.5.2 Chart - Global Market by Marker - Base/Final Year Comparison
    • 7.5.3 Chart - Global Market by Marker - Base Year
    • 7.5.4 Chart - Global Market by Marker - End Year
    • 7.5.5 Chart - Global Market by Marker - Share by Year
    • 7.5.6 Chart - Global Market by Marker - Segments Growth
  • 7.6 Global Market by Product - Overview
    • 7.6.1 Table - Global Market by Product
    • 7.6.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 7.6.3 Chart - Global Market by Product - Base Year
    • 7.6.4 Chart - Global Market by Product - End Year
    • 7.6.5 Chart - Global Market by Product - Share by Year
    • 7.6.6 Chart - Global Market by Product - Segments Growth

8 Global Liquid Biopsy Diagnostic Markets - By Cancer

  • 8.1 Breast
    • 8.1.1 Table Breast - by Country
    • 8.1.2 Table Breast - by Country, Price
    • 8.1.3 Table Breast - by Country Volume
    • 8.1.4 Chart - Breast Growth
  • 8.2 Colorectal
    • 8.2.1 Table Colorectal - by Country
    • 8.2.2 Table Colorectal - by Country, Price
    • 8.2.3 Table Colorectal - by Country, Volume
    • 8.2.4 Chart - Colorectal Growth
  • 8.3 Cervical
    • 8.3.1 Table Cervical - by Country
    • 8.3.2 Table Cervical - by Country, Price
    • 8.3.3 Table Cervical - by Country, Volume
    • 8.3.4 Chart - Cervical Growth
  • 8.4 Lung
    • 8.4.1 Table Lung - by Country
    • 8.4.2 Table Lung - by Country, Price
    • 8.4.3 Table Lung - by Country, Volume
    • 8.4.4 Chart - Lung Growth
  • 8.5 Prostate
    • 8.5.1 Table Prostate - by Country
    • 8.5.2 Table Prostate - by Country, Price
    • 8.5.3 Table Prostate - by Country, Volume
    • 8.5.4 Chart - Prostate Growth
  • 8.6 Other
    • 8.6.1 Table Other - by Country
    • 8.6.2 Table Other - by Country, Price
    • 8.6.3 Table Other - by Country, Volume
    • 8.6.4 Chart - Other Growth

9 Global Liquid Biopsy Diagnostic Markets - by Usage

  • 9.1 Screening
    • 9.1.1 Table Screening - by Country
  • 9.2 Chart - Screening Growth
  • 9.3 Diagnostic
    • 9.3.1 Table Diagnostic - by Country
    • 9.3.2 Chart - Diagnostic Growth
  • 9.4 Therapy
    • 9.4.1 Table Therapy - by Country
    • 9.4.2 Chart - Therapy Growth
  • 9.5 Monitor
    • 9.5.1 Table Monitor - by Country
    • 9.5.2 Chart - Monitor Growth

10 Global Liquid Biopsy Diagnostic Markets - by Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Lab Service
    • 10.2.1 Table Lab Service - by Country
    • 10.2.2 Chart - Lab Service Growth
  • 10.3 Lab Outpatient
    • 10.3.1 Table Lab Outpatient - by Country
    • 10.3.2 Chart - Lab Outpatient Growth
  • 10.4 Other Lab
    • 10.4.1 Table Other Lab - by Country
    • 10.4.2 Chart - Other Lab Growth

11 Global Liquid Biopsy Diagnostic Markets - by Marker

  • 11.1 Circulating Tumor Cell
    • 11.1.1 Table Circulating Tumor Cell - by Country
    • 11.1.2 Chart - Circulating Tumor Cell Growth
  • 11.2 Cell Free DNA
    • 11.2.1 Table Cell Free DNA - by Country
    • 11.2.2 Chart - Cell Free DNA Growth
  • 11.3 Vesicle
    • 11.3.1 Table Vesicle - by Country
    • 11.3.2 Chart - Vesicle Growth
  • 11.4 Other Marker
    • 11.4.1 Table Other Marker - by Country
    • 11.4.2 Chart - Other Marker Growth

12 Global Liquid Biopsy Diagnostic Markets - by Product

  • 12.1 Kits
    • 12.1.1 Table Kits - by Country
    • 12.1.2 Chart - Kits Growth
  • 12.2 Instruments
    • 12.2.1 Table Instruments - by Country
    • 12.2.2 Chart - Instruments Growth
  • 12.3 Service
    • 12.3.1 Table Service - by Country
    • 12.3.2 Chart - Service Growth

13 Appendices

  • 13.1 Growth of Approved IVD Test Menu
  • 13.2 Growth of Approved Average IVD Test Fee
  • 13.3 The Most Used IVD Assays
  • 13.4 The Highest Grossing Assays
  • 13.5 Laboratory Fees Schedule

Table of Tables

  • Table 1 Market Players by Type
  • Table 2 Biopsy Sites
  • Table 3 LB Clinical Applications by Entity
  • Table 4 Advantages of Liquid Biopsy in Screening Market
  • Table 5 Outlook - Phases of Liquid Biopsy Adoption by Year
  • Table 6 Five Factors Driving Growth
  • Table 7 Factors Limiting Growth
  • Table 8 Key Diagnostic Laboratory Technology Trends
  • Table 9 Next Generation Sequencing Technologies - Speed and Cost
  • Table 10 - Global Market by Region
  • Table 11 Global Market by Cancer
  • Table 12 Global Market by Usage
  • Table 13 Global Market by Place
  • Table 14 Global Market by Marker
  • Table 15 Global Market by Product
  • Table 16 Breast by Country
  • Table 17 Breast by Country Price
  • Table 18 Breast by Country Volume
  • Table 19 Colorectal by Country
  • Table 20 Colorectal by Country Price
  • Table 21 Colorectal by Country Volume
  • Table 22 Cervical by Country
  • Table 23 Cervical by Country Price
  • Table 24 Cervical by Country Volume
  • Table 25 Lung by Country
  • Table 26 Lung by Country Price
  • Table 27 Lung by Country Volume
  • Table 28 Prostate by Country
  • Table 29 Prostate by Country Price
  • Table 30 Prostate by Country Volume
  • Table 31 Other by Country
  • Table 32 Other by Country Price
  • Table 33 Other by Country Volume
  • Table 34 Screening by Country
  • Table 35 Diagnostic by Country
  • Table 36 Therapy by Country
  • Table 37 Monitor by Country
  • Table 38 Hospital Lab by Country
  • Table 39 Lab Service by Country
  • Table 40 Lab Outpatient by Country
  • Table 41 Other Lab by Country
  • Table 42 Circulating Tumor Cell by Country
  • Table 43 Cell Free DNA by Country
  • Table 44 Vesicle by Country
  • Table 45 Other Marker by Country
  • Table 46 Kits by Country
  • Table 47 Instruments by Country
  • Table 48 Service by Country
  • Table 49 The Most Common Assays
  • Table 50 Largest Revenue Assays
  • Table 51 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Global Healthcare Spending Picture
  • Figure 2 The Global Lab Test Pie
  • Figure 3 The Road to Diagnostics
  • Figure 4 Comparison of Liquid vs Tissue Biopsy
  • Figure 5 Entities Analyzed in liquid Biopsy
  • Figure 6 Characteristics of Different Vesicle Types
  • Figure 7 The Changing Age of World Population
  • Figure 8 Health Care Consumption by Age
  • Figure 9 Cancer Incidence - Age at Diagnosis
  • Figure 10 Global Market Regional Share Chart
  • Figure 11 Global Market by Cancer - Base vs. Final
  • Figure 12 Global Market by Cancer Base Year
  • Figure 13 Global Market by Cancer End Year
  • Figure 14 Cancer Share by Year
  • Figure 15 Cancer Segments Growth
  • Figure 16 Global Market by Usage - Base vs. Final
  • Figure 17 Global Market by Usage Base Year
  • Figure 18 Global Market by Usage End Year
  • Figure 19 Usage Share by Year
  • Figure 20 Usage Segments Growth
  • Figure 21 Global Market by Place - Base vs. Final
  • Figure 22 Global Market by Place Base Year
  • Figure 23 Global Market by Place End Year
  • Figure 24 Place Share by Year
  • Figure 25 Place Segments Growth
  • Figure 26 Global Market by Marker - Base vs. Final
  • Figure 27 Global Market by Marker Base Year
  • Figure 28 Global Market by Marker End Year
  • Figure 29 Marker Share by Year
  • Figure 30 Marker Segments Growth
  • Figure 31 Global Market by Product - Base vs. Final
  • Figure 32 Global Market by Product Base Year
  • Figure 33 Global Market by Product End Year
  • Figure 34 Product Share by Year
  • Figure 35 Product Segments Growth
  • Figure 36 Breast Growth
  • Figure 37 Colorectal Diagnostics Growth
  • Figure 38 Cervical Growth
  • Figure 39 Lung Growth
  • Figure 40 Prostate Growth
  • Figure 41 Other Growth
  • Figure 42 Screening Growth
  • Figure 43 Diagnostic Growth
  • Figure 44 Therapy Growth
  • Figure 45 Monitor Growth
  • Figure 46 Hospital Lab Growth
  • Figure 47 Lab Service Growth
  • Figure 48 Lab Outpatient Growth
  • Figure 49 Other Lab Growth
  • Figure 50 Circulating Tumor Cell Growth
  • Figure 51 Cell Free DNA Growth
  • Figure 52 Vesicle Growth
  • Figure 53 Other Marker Growth
  • Figure 54 Kits Growth
  • Figure 55 Instruments Growth
  • Figure 56 Service Growth
  • Figure 57 IVD Test Menu Growth
  • Figure 58 IVD Test Average Fees - A Ten Year View